S-ICD is effective in preventing sudden death in Arrhythmogenic Cardiomyopathy athletes during exercise by V. Catto et al.

 
 
 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/pace.13702. 
 
This article is protected by copyright. All rights reserved. 
 
 
S-ICD is effective in preventing sudden death in Arrhythmogenic Cardiomyopathy athletes during exercise 
 
Valentina Catto
1
*, PhD, Maria Antonietta Dessanai
1
*, MD, Elena Sommariva
2
, PhD, Claudio Tondo
1,3
, MD, 
PhD, FESC, Antonio Dello Russo
1
, MD, PhD
 
*equal contribution 
1
Heart Rhythm Center, Centro Cardiologico Monzino IRCCS, Milan, Italy. 
2
Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, Milan, Italy. 
3
Clinical Science and Community Department, Università degli Studi di Milano, Milan, Italy. 
 
Running Title: S-ICD in ACM athletes 
 
Total number of tables: 1 
Total number of figures: 1 
 
Financial support: none. 
 
Correspondence to: Dr. Antonio Dello Russo, Heart Rhythm Center, Centro Cardiologico Monzino IRCCS, Via 
Carlo Parea 4, 20138 Milan, Italy; e-mail address: antonio.dellorusso@ccfm.it; phone number +390258002739; 
Fax: +390258002782 
 
Disclosures. Prof. Claudio Tondo serves as member of EU Medtronic Advisory Board and Boston Scientific 
Advisory Board. The other authors declare no relationships with industry.  
 
 
 
 2 
 
Abstract 
Here we describe the cases of two elite athletes, with a diagnosis of Arrhythmogenic Cardiomyopathy (ACM), 
in which a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) has been implanted. Both patients 
experienced a ventricular tachycardia during exercise and received effective S-ICD shocks that interrupted 
arrhythmias. This report reveals for the first time that the S-ICD is effective in reverting arrhythmias in ACM 
patients, even during exercise. Moreover, these cases may confirm that competition/physical activity is 
associated with ICD shocks. 
Keywords: subcutaneous ICD, arrhythmogenic cardiomyopathy, elite athletes, efficacy, ventricular 
tachycardia. 
 
Introduction 
Arrhythmogenic Cardiomyopathy (ACM) is a genetic disease characterized by ventricular arrhythmias that may 
lead to sudden cardiac death.  
Diagnosis is reached when different major or minor criteria, established by the 2010 Task Force
1
, are met, 
which include imaging criteria, bioptic tissue results, electrocardiographic (ECG) features, arrhythmia presence 
and characteristics, and family history. 
Intense physical exercise is recognized as a trigger of life-threating arrhythmic events. Indeed, athletes have an 
increased risk of sudden cardiac death
2
. The most used therapy to prevent such events is the implantation of 
an Implantable Cardioverter Defibrillator (ICD). Indeed, ICD is widely used and effective protects the athlete 
population during competition and exercise
3,4
. In ACM patients, endurance and dynamic exercise may be 
strictly related to the phenotype severity, both as cardiac function deterioration and as precocity of major 
ventricular arrhythmic events
5
. 
Current guidelines
6,7
 recommend an ICD implantation for ACM patients with a history of aborted sudden 
cardiac death and hemodynamically poorly tolerated ventricular tachycardia (VT; recommendation class I level 
C), as well as in primary prevention for ACM patients with hemodynamically-tolerated sustained VT 
(recommendation class IIa level B).  
Despite its life-saving potential, ICD implantation is associated with a high rate of complications and significant 
impact on quality of life. Among complications, during implantation, pneumothorax, hemothorax, and cardiac 
tamponade could occur, while in the long term, lead dislodgement, fracture or defect can cause the loss of 
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effectiveness of the ICD system, or inappropriate shocks
8
. When indicated, lead extraction is a complex 
procedure, associated with important comorbidity and mortality. In recent years, the Subcutaneous ICD (S-ICD) 
has been developed to treat ventricular arrhythmias, without the need for the lead placement within or on the 
heart
9
. However, S-ICD efficacy has been evaluated only partially respect to all the possible applications where 
it could substitute transvenous ICD. In particular, its efficacy in ACM patients undergoing intense physical 
exercise has never been tested. This report describes the cases of two elite athletes diagnosed with ACM, in 
which S-ICD has demonstrated life-saving by defibrillating high frequency VT during sport activities. 
 
Case Reports 
Case 1: A 21-years old male elite basketball player was admitted to our Center after a cardiac arrest caused by 
ventricular fibrillation (VF) during a competition. He was immediately treated with cardiopulmonary 
resuscitation and seven external defibrillation shocks, allowing the successful conversion to sinus rhythm. After 
stabilization, the patient underwent non-invasive and invasive evaluations: electrocardiogram was normal; 
cardiac magnetic resonance (CMR) showed a biventricular dilatation compatible with training and a dubious 
delayed enhancement area near tricuspid valve; coronary angiography resulted normal; electroanatomical 
mapping (CARTO System, Biosense Webster) of both ventricles did not detect low-voltage areas and late 
potentials; the histological examination of endomyocardial byoptic samples did not show pathological findings. 
An S-ICD (Boston Scientific) was proposed for secondary prevention. The S-ICD had two therapy zones 
programmed: 220-250 beats/min (conditional zone) and >250 beats/min (shock zone) with sensing selected in 
the primary vector (1x gain).  
ACM diagnosis was confirmed by genetic analysis and by CMR at follow-up (delayed enhancement in right 
ventricle (RV)), both major criteria
1
.  
The patient was disqualified from competitive sport activities. 
One year after S-ICD implantation, the patient was admitted to our emergency unit for an S-ICD shock 
occurred during non-competitive exercise (basketball playing; sinus rhythm frequency preceding VT: 150 
beats/min). The S-ICD interrogation documented a 250 beats/min VT induced by exercise. The VT was 
interrupted after 16 sec with a shock of 65 J (Figure 1 A). 
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Case 2: A 20-years old male elite cyclist was admitted to our center for palpitations, pre-syncope, non-
sustained VT and ventricular premature complexes (left bundle branch block and superior axis) during a 
competition. ECG showed mild ST-segment elevation in V2-V4 and negative T waves in DII, DIII, aVF. CMR 
documented right and left ventricle dilatation with RV dyskinesia, end-diastolic volume to BSA 138ml/m
2
 and a 
delayed enhancement area in the posterolateral wall of left ventricle, suggestive of fatty tissue infiltration. 
RV electroanatomical mapping (EnSite NAvX System, Abbott) showed a small low-voltage area in the RV 
outflow tract. The electrophysiological study induced a monomorphic hemodynamically tolerated sustained 
VT. The histological examination of endomyocardial biopsies revealed increased cardiomyocyte size with 
irregular nuclei, signs of necrosis and fibro-fatty substitution, compatible with ACM.  
The diagnosis of ACM was therefore reached
1
. The genetic analysis did not reveal any ACM associated 
mutation. 
A primary prevention S-ICD implantation was proposed. The S-ICD had two therapy zones programmed: 220-
240 beats/min (conditional zone) and >240 beats/min (shock zone) with sensing selected in the primary vector 
(1x gain). 
The patient was disqualified from competitive sport activities and β-blocker therapy was recommended. 
Tre months after S-ICD implantation, the remote system latitude allowed the detection of four episodes of 240 
beats/min VT, preceded by a sinus tachycardia of 150 beats/min. All VTs were interrupted after 14-20 sec with 
65 J shocks (Figure 1 B). The patient was immediately contacted and confirmed having perceived shocks during 
exercise (cycling).  
 
Characteristics of both patients are summarized in Table 1. 
 
Discussion 
The described patients represent emblematic cases demonstrating the efficacy of the S-ICD, implanted either 
in primary or secondary prevention in elite athletes diagnosed with ACM. A very recent paper, indeed, 
reported S-ICD efficacy to treat ventricular arrhythmias in ACM patients
10
, though no attention was devoted to 
the subcategory of athletes. 
Despite competitive sport disqualification for the diagnosis of ACM, as recommended by the 2017 VA/SCD 
Guidelines
7
, the two described athletes underwent non-competitive intense exercise, which triggered VT, 
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requiring S-ICD interventions. Even if there is a general consensus that exercise training, in patients with an 
ICD, seems to be safe and not associated with increased risk of shocks
11
, it might not be the case for specific 
diseases such as ACM. In this case, the genetic predisposition may increment the effect of intense physical 
exercise, both from the point of view of heart muscle stretching, and for the augmented adrenergic 
stimulation adverse effect. The two phenomena may result in a greater arrhythmic burden in ACM patients 
during physical activity. Moreover, sympathetic activation may, in some cases, determine a defibrillation 
threshold increase and ineffective shocks
12
. However, in our cases, we observed a fast recognition and 
treatment of arrhythmias by the S-ICD during exercise. This supports the fact that S-ICD is protective even in 
patient practicing intense physical activity. 
The decision of implanting an S-ICD was taken in view of the young age of the patients: indeed the lack of 
transvenous access avoids the risks of catheter damage and infections during the long life expectancy with the 
ICD. Moreover, the S-ICD device easily allows CMR follow-up, particularly important for ACM disease 
progression monitoring
13
.  
To the best of our knowledge, to date no reports described S-ICD use in ACM athletes nor the S-ICD efficacy in 
discriminating high frequency heart rhythm (due to intense exercise) from VT, and in interrupting life-
threatening VT. Indeed, S-ICD are susceptible to T-wave oversensing caused by high rate-dependent ECG 
changes during exercise, leading to inappropriate shocks as highlighted for ACM by a previous work
14
. 
However, preimplantation screening methods (i.e. Automatic Screening Tool), algorithm updates (i.e. SMART 
PASS Filter) and experience have evolved
15
, reducing inappropriate shock rate, as demonstrated by the 
Effortless study
16
. 
In conclusion, from these cases we could draw the following messages: I) S-ICD is effective in reverting life-
threating arrhythmias in ACM patients, even during exercise; II) strenuous activity may induce ICD shocks in 
ACM patients, and possibly disease progression, therefore sport restriction should be recommended. 
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Figure Legend 
 
 
Figure 1. S-ICD registrations of the described events induced by exercise. A) Case 1: S-ICD shock after 16 sec of 
250 beats/min VT. B) Case 2: S-ICD shock after 14 sec of 240 beats/min VT. 
 
 
 
 
 
 
 
 
 
 
 9 
 
Table 1. Patients’ characteristics. 
 
NSVT: Non-sustained ventricular tachycardia; PVC: premature ventricular contractions; LBBB: left bundle 
branch block. 
 
 
 
Case 
n. 
Age/ 
sex 
Type 
of 
sport 
Type of 
spontaneous 
arrhythmias 
Symptoms 
Previous 
cardiac 
arrest 
ACM 
criteria 
Genetics 
s-ICD 
implantation 
for 
1 
21 / 
Male 
Basket 
Ventricular 
fibrillation 
- Yes 
2 
major 
PKP2:  
c.2009delC 
(pathogenic) 
RYR2: 
c.10355T>C 
(variant of 
unknown 
significance) 
secondary 
prevention 
2 
20 / 
Male 
Cycling 
NSVT and 
PVC (LBBB 
and superior 
axis) 
Palpitation, 
pre-
syncope 
No 
3 
major 
Negative 
primary 
prevention 
